Mithra announces 2018 financial calendar

LLiège, Belgium 17 January 2018 – Mithra (Euronext Brussels: MITRA), a company focused on women’s health, today announces its financial calendar for 2018: 2 March 2018: Full Year Results 2017 16 April 2018: Annual Report 2017 17 May 2018: Annual General Meeting 2018 25 September 2018: Half Year Results 2018 This schedule is indicative and […]

Mithra and Adamed Sign Commercialization Agreement for Myring™ in the Czech Republic

Mithra grants non-exclusive 10-year license for vaginal contraception ring MyringTM to Adamed for commercialization in the Czech Republic Agreement follows US and Austrian license granted to Mayne Pharma and Gynial, respectively MyringTM to be manufactured at Mithra CDMO Liège, Belgium, 27 December 2017 –  Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today […]

Mithra Announces Injectables Agreement with GSP

Mithra closes contracts with leading generics player GSP for development and supply of 4 hormonal injectables Contracts should allow for European and US GMP approval of injectable section at Mithra CDMO Strong validation by reputable partner of know-how and capabilities of Mithra CDMO Liège, Belgium, 14 December 2017 – Mithra (Euronext Brussels: MITRA), a company […]

Mithra Finalizes Estelle® Contract with Brazilian Women’s Health Leader Libbs

Mithra is eligible for a EUR 20 million upfront milestone payment, with EUR 14 million to be received in 2017 20-year contract grants Libbs an exclusive commercial license as well as manufacturing rights for Estelle® in Brazil, in addition to a cost-effective alternative supply option for key APIs (Active Pharmaceutical Ingredients) Contract forms part of […]

Mithra Announces Valorization of French Subsidiary

Liège, Belgium, 7 December 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces that it successfully divested its French affiliate, Mithra France.

Mithra Provides Update on Estelle® and Donesta® Studies

Liège, Belgium, 30 November 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces an update on the clinical study progress for its two lead Estetrol (E4) based product candidates, Estelle® (E4 Freedom) and Donesta® (E4 Relief).

Mithra Confirms Conversion of Subscription Rights

Liège, Belgium, 29 November 2017 – 18:00 – Regulated Information – Following press release issued on 30 October 2017, Mithra (Euronext Brussels: MITRA) today confirms, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 724,350 ordinary shares have been issued by […]

Mithra Announces 36-month Shelf Life Extension for Tibelia®

Extended shelf-life offers competitive advantage over current tibolone-based products, including originator product Livial® Tibelia® is currently marketed in 5 countries through existing supply and license agreements, with further contracts and product launches planned in coming months Liège, Belgium, 22 novembre 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today confirms the […]

Mithra Announces Positive Outcome of Myring™ Commercial Batch Bioequivalence Study

Bioequivalence study performed on commercial Myring™ batch produced at Mithra CDMO Data will form part of planned Myring™ FDA filing by US partner Mayne Pharma Liège, Belgium, 17 November 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, announces the successful outcome of a confirmatory bioequivalence study performed on a commercial batch […]

Mithra Announces Launch of Warrant Exercise Period

Liège, Belgium, 30 October 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces the launch of an exercise period of its warrant plan initiated on 2 March 2015.